FindTrial
Sign In

Measurement of change in eGFR levels with primary drugs used in heart failure with chronic kidney disease

Prospective evaluation of eGFR changes during therapy optimization in heart failure patients with chronic kidney disease - NO

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/10/096455
Enrollment
154
Registered
2025-10-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N189- Chronic kidney disease, unspecified Health Condition 2: I501- Left ventricular failure, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

All India Institute Of Medical Sciences Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of age 18 year to 80 year and of either sex. 2. Patients of Heart failure with reduced ejection fraction. 3. Patients with eGFR less than 90 ml per min per 1.73 m2 at screening.

Exclusion criteria

Exclusion criteria: 1. Patients who are already on any of the first-line heart failure drugs for other indications. 2. Patients with preserved ejection fraction. 3. Patients with raised AST/ALT more than 3 times from baseline. 4. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Mean change in eGFR levels from baseline to 16 weeks.Timepoint: baseline, 16 weeks.—

Secondary

MeasureTime frame
1. Mean change in eGFR levels from baseline to 16 weeks based on type of therapeutic intervention. 2. Mean change in eGFR levels from baseline to 16 weeks based on chronic kidney disease (CKD) stages. 3. Corelation between mean change in eGFR with NT-pro BNP and GDF-15 levels from baseline to 16 weeks among HFrEF and CKD patients having diabetes. 4. Cost effectiveness analysis of first line drug therapy used in HErEF with CKD patients over 16 weeks. 5. Safety profile of first line drug therapy used in HErEF with CKD patients over 16 weeks. 6. Change in Health status from baseline to 16 weeks based on KCCQ-OSS Score.Timepoint: baseline, 16th week—

Countries

India

Contacts

Public ContactDr Dharmin Maheshbhai Patel

All India Institute Of Medical Sciences, Jodhpur

drshobanpgimer@gmail.com8437726777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026